An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera

NCT ID: NCT07148999

Last Updated: 2025-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-23

Study Completion Date

2026-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical trial will determine the effectiveness of using the Opt-IVF decision support tool for each patient's personalized and optimal drug dosage profile in the United States.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a two-arm randomized clinical trial involving more than 100 patients; one arm will undergo superovulation using dosages predicted by the decision support tool, while the other will undergo the current standard treatment. The research question is whether outcomes of patient dosage treatment using Opt-IVF are better or similar to the current practice. We will compare the outcomes of the two groups of patients in terms of the numbers and percentage of mature follicles retrieved at the end of each cycle, total FSH and HMG dosages used, and the number of required testing days for that cycle, total number of M2s, Number of embryos, Number of Grade A embryos and Number of Grade A blastocysts.

The trial is for research purposes only. The current tool has not been submitted for any regulatory body approval.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility (IVF Patients)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The primary protocol used in this trial is a progesterone-primed ovarian stimulation (PPOS).

This is a multi-site cohort with two arms (one arm for the intervention and one arm for the traditional approach), a randomized clinical trial involving more than 100 patients. The clinical trial will be registered on ClinicalTrials.gov. It is a parallel trial with a 1:1 allocation. A Simple Randomization method will assign patients to the intervention and control groups using a lottery method. The generation of random sequences will be carried out by Dr. Diwekar, who will not be involved in the clinical administration of the trial. The patients will be registered and assigned to different groups separately at each center. The allocation will be masked until participants are ready to receive the intervention. An administrator, who will not be a clinical investigator, will allocate a participant to one arm using the random sequences generated prior to the trial. The clinicians, participants,
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

This arm will get dosage prescribed by the doctor

Group Type ACTIVE_COMPARATOR

Control

Intervention Type OTHER

Physicians will decide the dosage for each day for patients

Opt-IVF

This arm patients will get dosage provided by Opt-IVF

Group Type EXPERIMENTAL

Opt-IVF

Intervention Type COMBINATION_PRODUCT

Opt-IVF provides optimized dosage profile for each patient

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Opt-IVF

Opt-IVF provides optimized dosage profile for each patient

Intervention Type COMBINATION_PRODUCT

Control

Physicians will decide the dosage for each day for patients

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* infertile women

Exclusion Criteria

All female patients who will not undergo IVF or whose cycles will be converted to IUI. Male patients will not be enrolled in this study. No donor cycles.
Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IVF Academy of USA

UNKNOWN

Sponsor Role collaborator

Positivf Fertility

UNKNOWN

Sponsor Role collaborator

Urmila DIwekar

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Urmila DIwekar

President

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Magarelli, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

IVF Academy USA

Francesco Arredondo, MD, Ph.D.

Role: STUDY_DIRECTOR

Positivf Fertility

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Positivf Fertility

Houston, Texas, United States

Site Status RECRUITING

Positivf Fertility

San Antonio, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Urmila Diwekar, Ph.D.

Role: CONTACT

6308863047

Sanjay Joag, M.D., Ph.D.

Role: CONTACT

6305014451

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paul Magarelli, MD, Ph.D.

Role: primary

719-331-6392

Francisco Arrendendo, MD, MPh

Role: primary

210-404-2229

References

Explore related publications, articles, or registry entries linked to this study.

Diwekar et al., A multicenter randomized clinical trial with a novel decision support tool to improve IVF success, Reproduction and Fertility, 6(3), e250004, 2025.DOI: https://doi.org/10.1530/RAF-25-0004

Reference Type BACKGROUND

Diwekar U, Gupta S, Gahlan A, Hota S, Murdia K, Murdia N, Chandra V, Bhoi N, Joag S. A new decision-support tool in a multi-center randomized trial for personalized, optimized, and simplified fertility treatment in non-PCOS patients. Reprod Fertil. 2024 Sep 16;5(3):e240013. doi: 10.1530/RAF-24-0013. Print 2024 Jul 1.

Reference Type BACKGROUND
PMID: 39159260 (View on PubMed)

Nisal A, Diwekar U, Bhalerao V. Personalized medicine for in vitro fertilization procedure using modeling and optimal control. J Theor Biol. 2020 Feb 21;487:110105. doi: 10.1016/j.jtbi.2019.110105. Epub 2019 Dec 3.

Reference Type BACKGROUND
PMID: 31809718 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://opt-ivf.com/studies.html

all clinical publications are available here

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PPOS-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.